全髋关节翻修术治疗骨折:费用更高、并发症更多、诊断相关分组相同:一项本地与全国队列研究
该研究回顾性分析高容量中心2009至2014年1422例无菌性全髋翻修术的住院费用和并发症,并利用NIS和ACS-NSQIP数据比较骨折、磨损/松动、脱位/不稳三种指征的费用与30天并发症。结果显示骨折翻修费用比其它无菌指征高33%至48%,且30天并发症率更高,而现行DRG未区分翻修指征。
要点
- 骨折翻修住院费用中位数本地$25,672、全国$27,596,均高于磨损/松动和脱位/不稳。
- 本地30天骨科并发症率骨折20.7%,高于脱位/不稳9.0%,与磨损/松动17.6%相似。
- 全国30天合并医疗和手术并发症率骨折71.3%,显著高于磨损/松动35.2%和脱位/不稳35.1%。
核心结论
- 骨折翻修住院费用比所有其它无菌翻修高33%至48%,本地和全国一致,且多变量合并症调整后仍显著。
- 30天并发症率提示骨折患者出院后资源利用仍增加,需要针对指征的编码和报销系统。
研究设计与样本
- 回顾性分析高容量中心2009至2014年1422例无菌性全髋翻修术的住院费用和并发症率。
- 将全国住院患者样本(NIS)中28133例翻修全髋的收费经HCUP成本-收费比转换为成本,并用ACS-NSQIP获取3224例翻修全髋的30天并发症率。
- 采用同时和两两比较及多变量模型(校正ASA评分、年龄和性别)比较骨折、磨损/松动和脱位/不稳翻修的费用与并发症。
主要发现
- 本地住院费用中位数:骨折$25,672,高于磨损/松动$20,228(p < 0.001)和脱位/不稳$17,911(p < 0.001),校正合并症后差异仍显著(p < 0.001)。
- NIS费用中位数:骨折$27,596,高于磨损/松动$21,176(p < 0.001)和脱位/不稳$16,891(p < 0.001)。
- 本地30天骨科并发症率:骨折20.7%,高于脱位/不稳9.0%(p = 0.007),与磨损/松动17.6%相似(p = 0.434)。
- 全国30天合并医疗和手术并发症率(≥1种并发症患者比例):骨折71.3%,显著高于磨损/松动35.2%(p < 0.001)和脱位/不稳35.1%(p < 0.001)。
关键数值与推荐
- 骨折翻修住院费用比所有其它无菌翻修高33%至48%,本地和全国一致。
- 现行DRG 466、467、468未考虑翻修病因。
- 证据等级:预后Level III。
临床怎么用
- 作者认为需要针对指征的编码和报销系统,以维持所有患者可持续获得翻修全髋关节置换术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Revision total hip arthroplasty (revision THA) occurs for a wide variety of indications and in the United States it is coded under Diagnosis-Related Groups (DRGs) 466, 467, and 468, which do not account for revision etiology, a potentially substantial driver of cost. This study investigates revision THA costs and 30-day complications by indication, both locally and nationally. METHODS: Hospitalization costs and complication rates for 1,422 aseptic revision THAs performed at a high-volume center between 2009 and 2014 were retrospectively reviewed. Additionally, charges for 28,133 revision THAs in the National Inpatient Sample (NIS) were converted to costs using the Healthcare Cost and Utilization Project cost-to-charge ratios, and 30-day complication rates for 3,224 revision THAs were obtained with use of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). Costs and complications were compared between revision THAs performed for fracture, wear/loosening, and dislocation/instability with use of simultaneous and pairwise comparisons and a multivariable model accounting for American Society of Anesthesiologists (ASA) score, age, and sex. RESULTS: Local hospitalization costs for fracture (median, $25,672) were significantly higher than those for wear/loosening ($20,228; p < 0.001) or dislocation/instability ($17,911; p < 0.001), with differences remaining significant even after adjusting for patient comorbidities (p < 0.001). NIS costs for fracture (median, $27,596) were higher than those for other aseptic indications (wear/loosening: $21,176, p < 0.001; dislocation/instability: $16,891, p< 0.001). Local 30-day orthopaedic complication rates for fracture (20.7%) were higher those than for dislocation/instability (9.0%; p = 0.007) and similar to those for wear/loosening (17.6%; p = 0.434). Nationally, combined medical and surgical complication rates for fracture (71.3% of patients with ≥1 complication) were significantly higher than those for wear/loosening (35.2%; p < 0.001) or dislocation/instability (35.1%; p < 0.001). CONCLUSIONS: Hospitalization costs for revision THA for fracture were 33% to 48% higher than for all other aseptic revision THAs, both locally and nationally. This increased cost persisted even after multivariable comorbidity adjustment, the current DRG basis for stratifying revision THA reimbursement. Additionally, 30-day complication rates suggest that increased resource utilization for fracture patients continues even after discharge. Indication-specific coding and reimbursement systems are necessary to maintain sustainable access to revision THA for all patients. LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Hevesi M, Wyles CC, Yao JJ, et al. Revision Total Hip Arthroplasty for the Treatment of Fracture: More Expensive, More Complications, Same Diagnosis-Related Groups: A Local and National Cohort Study. J Bone Joint Surg Am. 2019. PMID: 31094983. doi:10.2106/JBJS.18.00523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。